Phase 3 Clinical Trials

Late-stage Phase 3 clinical trial results and data readouts for biotech companies.

100 UpcomingView Full Calendar

January 20268

Jan 6

BNTX⭐Phase 3

BNT162b2 (Omi LP.8.1) Phase 3 Results Expected

BNT162b2 (Omi LP.8.1) • COVID-19

Jan 8

SNY⭐Phase 3

Yellow fever vaccine (live) Phase 3 Results Expected

Yellow fever vaccine (live) • Yellow Fever Immunization

Jan 12

MRK$245.9B⭐Phase 3

brentuximab vedotin Phase 3 Results Expected

brentuximab vedotin • Hodgkin Lymphoma

Jan 12

MRK$245.9B⭐Phase 3

pembrolizumab Phase 3 Results Expected

pembrolizumab • Non-small Cell Lung Cancer

Jan 2026~

PVLA$1.1B⭐Phase 3

QTORIN 3.9% Rapamycin Anhydrous Gel Phase 3 Results Expected

QTORIN 3.9% Rapamycin Anhydrous Gel • Microcystic Lymphatic Malformation

Jan 30

MRTX⭐Phase 3

Cetuximab Phase 3 Results Expected

Cetuximab • Advanced Colorectal Cancer

Jan 30

MRTX⭐Phase 3

MRTX849 Phase 3 Results Expected

MRTX849 • Advanced Cancer

Jan 31

KOD⭐Phase 3

Tarcocimab Phase 3 Results Expected

Tarcocimab • Diabetic Retinopathy

February 202615

Feb 2026~

NMRA$307M⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Major Depressive Disorder

Feb 2026~

KOD⭐Phase 3

KSI-101 Phase 3 Results Expected

KSI-101 • Macular Edema Secondary to Inflammation

Feb 2026~

OTSKF$34.0B⭐Phase 3

OPC-34712FUM/ Brexpiprazole fumarate Phase 3 Results Expected

OPC-34712FUM/ Brexpiprazole fumarate • Acute Schizophrenia

Feb 2026~

NMRA$307M⭐Phase 3

NMRA-335140 Phase 3 Results Expected

NMRA-335140 • Major Depressive Disorder

Feb 2026~

DAWN⭐Phase 3

Chemotherapeutic Agent Phase 3 Results Expected

Chemotherapeutic Agent • Low-grade Glioma

Feb 2026~

DAWN⭐Phase 3

Tovorafenib Phase 3 Results Expected

Tovorafenib • Low-grade Glioma

Feb 18

PFE$142.7B⭐Phase 3

talazoparib plus enzalutamide Phase 3 Results Expected

talazoparib plus enzalutamide • Prostate Cancer

Feb 20

NOVO-B.CO⭐Phase 3

Cagrilintide Phase 3 Results Expected

Cagrilintide • Obesity

Feb 20

NOVO-B.CO⭐Phase 3

Semaglutide Phase 3 Results Expected

semaglutide • Diabetes

Feb 20

NVO⭐Phase 3

Tirzepatide Phase 3 Results Expected

Tirzepatide • Diabetes Mellitus, Type 2

Feb 20

NVO⭐Phase 3

Semaglutide Phase 3 Results Expected

Semaglutide • Obesity

Feb 20

NVO⭐Phase 3

Cagrilintide Phase 3 Results Expected

Cagrilintide • Obesity or Overweight

Feb 20

NOVO-B.CO⭐Phase 3

Tirzepatide Phase 3 Results Expected

Tirzepatide • Type 2 Diabetes

Feb 25

INCY⭐Phase 3

Povorcitinib Phase 3 Results Expected

Povorcitinib • NonSegmental Vitiligo

Feb 28

4503.T⭐Phase 3

mirabegron Phase 3 Results Expected

mirabegron • Neurogenic Detrusor Overactivity

March 202622

Mar 1

EPZM⭐Phase 3

Placebo oral tablet Phase 3 Results Expected

Placebo oral tablet • Relapsed/Refractory Follicular Lymphoma

Mar 1

EPZM⭐Phase 3

Tazemetostat Phase 3 Results Expected

Tazemetostat • Diffuse Large B-cell Lymphoma (DLBCL)

Mar 1

WXI⭐Phase 3

CU-20101 treatment for Moderate to Severe Glabellar Striae Phase 3 Results Expected

CU-20101 treatment for Moderate to Severe Glabellar Striae • Glabellar Frown Lines

Mar 6

SNY⭐Phase 3

avalglucosidase alfa Phase 3 Results Expected

avalglucosidase alfa • Glycogen Storage Disease Type II

Mar 14

INSM⭐Phase 3

Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected

Treprostinil Palmitil Inhalation Powder • Pulmonary Hypertension

Mar 2026~

LLY⭐Phase 3

Orforglipron Phase 3 Results Expected

Orforglipron • Obesity

Mar 2026~

AARD$292M⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Hyperphagia

Mar 2026~

AMLX$1.3B⭐Phase 3

Avexitide Phase 3 Results Expected

Avexitide • Post Bariatric Hypoglycemia

Mar 2026~

RNA$10.8B⭐Phase 3

AOC 1001 (del-desiran) Phase 3 Results Expected

AOC 1001 (del-desiran) • DM1

Mar 2026~

ITCI⭐Phase 3

Lumateperone Phase 3 Results Expected

Lumateperone • Major Depressive Disorder

Mar 2026~

ITCI⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Psychosis Associated With Alzheimer's Disease

Mar 2026~

KPTI⭐Phase 3

Selinexor Phase 3 Results Expected

Selinexor • Multiple Myeloma, Refractory

Mar 2026~

MDGL⭐Phase 3

Resmetirom Phase 3 Results Expected

Resmetirom • NASH

Mar 2026~

LLY⭐Phase 3

Insulin Glargine Phase 3 Results Expected

Insulin Glargine • Diabetes Mellitus, Type 2

Mar 2026~

KRYS⭐Phase 3

KB803 Phase 3 Results Expected

KB803 • Dystrophic Epidermolysis Bullosa

Mar 2026~

KPTI⭐Phase 3

Ruxolitinib Phase 3 Results Expected

Ruxolitinib • Myelofibrosis

Mar 17

INCY⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Hidradenitis Suppurativa

Mar 25

OTSKF$34.0B⭐Phase 3

Centanafadine Hydrochloride Phase 3 Results Expected

Centanafadine Hydrochloride • Attention-Deficit/Hyperactivity Disorder

Mar 27

MLTX$1.0B⭐Phase 3

Sonelokimab Phase 3 Results Expected

Sonelokimab • Hidradenitis Suppurativa

Mar 31

URGN$1.1B⭐Phase 3

UGN-104 Phase 3 Results Expected

UGN-104 • Upper Urinary Tract Urothelial Carcinoma

Mar 31

4503.T⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Acute Myeloid Leukemia

Mar 31

4503.T⭐Phase 3

Fezolinetant Phase 3 Results Expected

Fezolinetant • Menopause

April 202616

Apr 1

INCY⭐Phase 3

Tafasitamab Phase 3 Results Expected

Tafasitamab • Diffuse Large B Cell Lymphoma

Apr 1

AMLX$1.3B⭐Phase 3

AMX0035 Phase 3 Results Expected

AMX0035 • Amyotrophic Lateral Sclerosis

Apr 1

PRTX⭐Phase 3

Open-label rusfertide Phase 3 Results Expected

Open-label rusfertide • Polycythemia Vera

Apr 1

INCY⭐Phase 3

Lenalidomide Phase 3 Results Expected

Lenalidomide • Large B-Cell Lymphoma

Apr 2026~

IONS⭐Phase 3

Eplontersen Phase 3 Results Expected

Eplontersen • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Apr 2026~

VTGN⭐Phase 3

Fasedienol Nasal Spray Phase 3 Results Expected

Fasedienol Nasal Spray • Social Anxiety Disorder (SAD)

Apr 2026~

AKRO⭐Phase 3

Efruxifermin Phase 3 Results Expected

Efruxifermin • NASH - Nonalcoholic Steatohepatitis

Apr 2026~

AKRO⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • NASH/MASH

Apr 2026~

LLY⭐Phase 3

Baricitinib Phase 3 Results Expected

Baricitinib • Systemic Juvenile Idiopathic Arthritis

Apr 2026~

LLY⭐Phase 3

Retatrutide Phase 3 Results Expected

Retatrutide • Obesity

Apr 17

SNY⭐Phase 3

Low Dose (LD) RSVt vaccine Phase 3 Results Expected

Low Dose (LD) RSVt vaccine • RSV Immunisation

Apr 21

NVO⭐Phase 3

Concizumab Phase 3 Results Expected

Concizumab • Congenital Bleeding Disorder

Apr 21

NOVO-B.CO⭐Phase 3

Concizumab Phase 3 Results Expected

Concizumab • Haemophilia A Without Inhibitors

Apr 29

OCUL⭐Phase 3

OTX-TKI (axitinib implant) Phase 3 Results Expected

OTX-TKI (axitinib implant) • Neovascular Age-Related Macular Degeneration

Apr 30

VRTX⭐Phase 3

ELX/TEZ/IVA Phase 3 Results Expected

ELX/TEZ/IVA • Cystic Fibrosis

Apr 30

VRTX⭐Phase 3

IVA Phase 3 Results Expected

IVA • Cystic Fibrosis

May 20268

May 2026~

ITCI⭐Phase 3

Lumateperone Phase 3 Results Expected

Lumateperone • Major Depressive Disorder

May 2026~

NMRA$307M⭐Phase 3

NMRA-335140 Phase 3 Results Expected

NMRA-335140 • Major Depressive Disorder

May 2026~

LLY⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Acute Pain

May 2026~

LLY⭐Phase 3

Tirzepatide Phase 3 Results Expected

Tirzepatide • Overweight

May 15

SNY⭐Phase 3

Venglustat (GZ402671) Phase 3 Results Expected

Venglustat (GZ402671) • Fabry Disease

May 2026~

ITCI⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Psychosis Associated With Alzheimer's Disease

May 31

VRTX⭐Phase 3

VX-147 Phase 3 Results Expected

VX-147 • Proteinuric Kidney Disease

May 31

VRTX⭐Phase 3

CTX001 Phase 3 Results Expected

CTX001 • Beta-Thalassemia

June 202612

Jun 2

NVO⭐Phase 3

Cagrilintide Phase 3 Results Expected

Cagrilintide • Obesity or Overweight

Jun 2

NVO⭐Phase 3

Tirzepatide Phase 3 Results Expected

Tirzepatide • Diabetes Mellitus, Type 2

Jun 2

NVO⭐Phase 3

Semaglutide Phase 3 Results Expected

Semaglutide • Obesity

Jun 2026~

RCUS⭐Phase 3

Domvanalimab Phase 3 Results Expected

Domvanalimab • Advanced Upper Gastrointestinal Tract Adenocarcinoma

Jun 2026~

IONS⭐Phase 3

ION363 Phase 3 Results Expected

ION363 • Amyotrophic Lateral Sclerosis

Jun 2026~

RVMD⭐Phase 3

RMC-6236 Phase 3 Results Expected

RMC-6236 • Colorectal Cancer

Jun 2026~

RVMD⭐Phase 3

Gemcitabine Phase 3 Results Expected

Gemcitabine • Pancreatic Cancer

Jun 16

BNTX⭐Phase 3

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Phase 3 Results Expected

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose • SARS-CoV-2 Virus

Jun 22

MRK$245.9B⭐Phase 3

Pembrolizumab (+) Berahyaluronidase alfa Phase 3 Results Expected

Pembrolizumab (+) Berahyaluronidase alfa • Lung Cancer

Jun 26

NOVO-B.CO⭐Phase 3

Ziltivekimab B Phase 3 Results Expected

Ziltivekimab B • Cardiovascular Risk

Jun 30

OLMA⭐Phase 3

Palazestrant Phase 3 Results Expected

Palazestrant • Breast Cancer

Jun 30

JNJ⭐Phase 3

JNJ-90301900 (NBTXR3) Phase 3 Results Expected

JNJ-90301900 (NBTXR3) • Locally Advanced Head and Neck Squamous Cell Carcinoma

July 20265

Jul 13

INCY⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Vehicle Cream • Prurigo Nodularis

Jul 13

INCY⭐Phase 3

Ruxolitinib Phase 3 Results Expected

Ruxolitinib • MPN (Myeloproliferative Neoplasms)

Jul 2026~

RARE⭐Phase 3

GTX-102 Phase 3 Results Expected

GTX-102 • Angelman Syndrome

Jul 2026~

LLY⭐Phase 3

Lebrikizumab Phase 3 Results Expected

Lebrikizumab • Atopic Dermatitis

Jul 2026~

LLY⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Acute Pain

August 202612

Aug 8

SNY⭐Phase 3

Yellow fever vaccine (live) Phase 3 Results Expected

Yellow fever vaccine (live) • Yellow Fever Immunization

Aug 8

SNY⭐Phase 3

Measles, combinations with mumps and rubella, live attenuated Phase 3 Results Expected

Measles, combinations with mumps and rubella, live attenuated • Yellow Fever Immunization

Aug 10

INCY⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Ruxolitinib Cream • Nonsegmental Vitiligo With Genital Involvement

Aug 2026~

EYPT$1.4B⭐Phase 3

Aflibercept (2.0 mg) Phase 3 Results Expected

Aflibercept (2.0 mg) • Wet Age Related Macular Degeneration

Aug 2026~

EYPT$1.4B⭐Phase 3

EYP-1901 Phase 3 Results Expected

EYP-1901 • Diabetic Macular Edema

Aug 2026~

KPTI⭐Phase 3

Selinexor Phase 3 Results Expected

Selinexor • Multiple Myeloma, Refractory

Aug 2026~

XENE⭐Phase 3

Azetukalner Phase 3 Results Expected

Azetukalner • Major Depressive Disorder

Aug 2026~

KPTI⭐Phase 3

Matching Placebo for selinexor Phase 3 Results Expected

Matching placebo for selinexor • Endometrial Cancer

Aug 2026~

KOD⭐Phase 3

Tarcocimab tedromer Phase 3 Results Expected

Tarcocimab tedromer • Wet Age-related Macular Degeneration

Aug 31

4503.T⭐Phase 3

Fezolinetant Phase 3 Results Expected

Fezolinetant • Menopause

Aug 31

4503.T⭐Phase 3

Placebo Phase 3 Results Expected

Placebo • Acute Myeloid Leukemia

Aug 31

4503.T⭐Phase 3

Tamoxifen Phase 3 Results Expected

Tamoxifen • Hot Flashes

September 20262

Sep 1

INCY⭐Phase 3

Cyclophosphamide Phase 3 Results Expected

Cyclophosphamide • Diffuse Large B-cell Lymphoma

Sep 1

TGTX⭐Phase 3

Ublituximab Phase 3 Results Expected

Ublituximab • Non-Hodgkins Lymphoma

Get Phase 3 Clinical Trials Alerts

About Phase 3 Clinical Trials

Late-stage Phase 3 clinical trial results and data readouts for biotech companies.

What is a Phase 3 Clinical Trial?

Phase 3 trials are large-scale studies that test a drug's efficacy and safety in hundreds to thousands of patients. Positive Phase 3 results typically lead to regulatory submission, while negative results can end a drug's development.